← Eichor
Condition: Indolent B Cell Non Hodgkin Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Indolent B Cell Non Hodgkin Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Phase 2 · 1 location(s) · Koo Foundation Sun Yat-Sen Cancer Center · NCT06461182Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed
Phase 2 · 6 location(s) · Academic and Community Cancer Research United · NCT06238648Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05672251Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06350318Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
Phase N/A · 1 location(s) · Azienda USL Reggio Emilia - IRCCS · NCT06822829MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Phase 1/Phase 2 · 1 location(s) · Beijing Mabworks Biotech Co., Ltd. · NCT04110301A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Phase 3 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07029217ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
NA · 1 location(s) · University Hospital Muenster · NCT04097067Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Phase 1 · 1 location(s) · Lapo Alinari · NCT05755087CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Phase 1 · 1 location(s) · Nathan Denlinger · NCT06209619A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi
Phase 2 · 1 location(s) · Shayna Sarosiek, MD · NCT06986174Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT07365306Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Phase 2 · 1 location(s) · University of Washington · NCT06784726Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of R
Phase 1 · 8 location(s) · National Cancer Institute (NCI) · NCT06015880The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
NA · 2 location(s) · Mayo Clinic · NCT05876923Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
Phase 2 · 7 location(s) · Mayo Clinic · NCT06386315A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Phase 1/Phase 2 · 27 location(s) · BioInvent International AB · NCT03571568A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Len
Phase 3 · 169 location(s) · Regeneron Pharmaceuticals · NCT06149286Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
NA · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06860880ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07098364Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Phase 2 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT06458439Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgk
Phase 2 · 1 location(s) · Emory University · NCT04883437Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Phase 2 · 1 location(s) · University of Washington · NCT06442475Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refracto
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT04223765Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Mali
Phase 1 · 2 location(s) · Sumithira Vasu · NCT05418088A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Di
Phase 3 · 190 location(s) · Regeneron Pharmaceuticals · NCT06091254SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT06544265A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 12 location(s) · Enterome · NCT04669171
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.